IBA Notice of Full Year 2022 Results and Conference Call
![](https://www.iba-worldwide.com/sites/all/themes/custom/protontherapy/assets/images/mb-room-header-xs.jpg)
Corporate
/
20.02.2023
FY22 results meeting to take place as a hybrid event on Thursday, 23 March 2023 at 3pm CET
Louvain-la-Neuve, Belgium, 20 February 2023 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, announces today that it will publish its consolidated results for the full year 2022 on Thursday, 23 March 2023 at 7am CET.
Conference Call Information
Olivier Legrain, Chief Executive Officer, and Soumya Chandramouli, Chief Financial Officer, will host a hybrid event to present the full year results, including a conference call and webcast, followed by a Q&A session.
The conference call, conducted in English, will be held on Thursday,23 March 2023 at 3pm CET / 2pm GMT / 10am EDT / 7amPDT as a Teams webinar and can be accessed online via this link.
If you would like to join by phone only, please dial (Phone conference ID 745 901 390#):
Belgium: +32 2 890 97 20
UK: +44 20 3321 5200
NL: +31 20 708 6901
LU: +352 27 87 00 02
US: +1 347-991-7591
FR: +33 1 70 99 53 51
The presentation will be available on IBA’s investor relations website and on:
https://www.iba-worldwide.com/content/iba-full-year-2022-results-press-release-publication-date-conference-call-details shortly before the call.
To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.
For participants who do not have the Teams application installed, please follow the process described in this link to access the conference.
ENDS
About IBA
IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 1,800 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.
IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
More information can be found at: www.iba-worldwide.com